seeking biotech alpha Sept 2019 & December 2018 insight

Nplate® (Romiplostim)

HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®

ADCETRIS® (brentuximab vedotin)

FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia

Fri December 14, 2018 4:00 PM|PR Newswire|About: AMGN

FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia Application Granted Priority Review Designation THOUSAND OAKS, Calif., Dec. 14, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN)

ADCETRIS® (brentuximab vedotin)

HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®

ADCETRIS® (brentuximab vedotin)

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD

Fri December 14, 2018 12:00 PM|Business Wire|About: TKPYY

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD – If Authorized in Europe, ADCETRIS in Combination with AVD (Adriamycin, Vinblastine and Dacarbazine) Will Be the First New Treatment Regimen Available for Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Decades –

HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®

ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin®* (bevacizumab),

Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications

Fri December 14, 2018 6:31 PM|Business Wire|About: TEVA

Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications December 14, 2018 06:31 PM Eastern Standard Time INCHEON, South Korea & JERUSALEM--(BUSINESS WIRE)--Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA

ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin®* (bevacizumab),

Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab)

Fri December 14, 2018 10:29 AM|Business Wire|About: PFE

Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab) ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin®* (bevacizumab), is Pfizer’s second therapeutic oncology biosimilar to receive a positive CHMP opinion in Europe in 2018 December 14, 2018 10:29 AM Eastern Standard Time NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE)

INGREZZA® (valbenazine)

ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin®* (bevacizumab),

Enfortumab Vedotin Plus Pembrolizumab

Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®

Tue September 17, 2019 4:11 PM|PR Newswire|About: NBIX

- Data Examine Effect of Opicapone on COMT Enzyme and Levodopa Concentration in Patients with Parkinson's Disease

- Phase 1b Data Analyze Parkinson's Disease Progression in Patients Treated with Gene Therapy, VY-AADC

PR Newswire

SAN DIEGO, Sept.17, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX)

https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-data-on-ingrezza-valbenazine-for-tardive-dyskinesia-opicapone-and-vy-aadc-for-parkinsons-disease-at-the-2019-international-congress-of-parkinsons-disease-and-movement-disorders-300920167.html

INGREZZA® (valbenazine) capsules is a prescription medicine used to treat adults with movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).

Enfortumab Vedotin Plus Pembrolizumab

ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin®* (bevacizumab),

Enfortumab Vedotin Plus Pembrolizumab

Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the European Society for Medical Oncology (ESMO) 2019 Congress

Tue September 17, 2019 8:00 AM|Business Wire|About: SGEN

– First Presentation of Initial Data from a Phase 1 Trial of Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer Featured in an Oral Session –

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN)

https://www.seattlegenetics.com/pipeline/enfortumab-vedotin

Tisotumab vedotin is an antibody-drug conjugate (ADC) composed of a human antibody targeted to tissue factor (TF) and our ADC technology that utilizes a protease-cleavable linker and the potent microtubule-disrupting agent monomethyl auristatin E (MMAE). TF is highly expressed on many solid tumors, including ovarian, prostate, bladder, esophageal, endometrial and lung. We are co-developing tisotumab vedotin with Genmab.

seeking biotech alpha Sept 2019 & December 2018 insight

Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy)

FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer

Thu December 6, 2018 5:11 PM|Business Wire|About: RHHBY

December 06, 2018 05:11 PM Eastern Standard Time FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer – Approval based on survival benefit of Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy), in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations compared to Avastin plus chemotherapy – SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY

Amgen (AMGN)

Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy)

Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend

Fri December 7, 2018 4:00 PM|PR Newswire|About: AMGN

Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend THOUSAND OAKS, Calif., Dec. 7, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN)

V920 is Merck's Investigational Vaccine for Ebola Zaire

Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy)

V920 is Merck's Investigational Vaccine for Ebola Zaire

FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus

Tue September 17, 2019 6:45 AM|Business Wire|About: MRK

Merck (MRK) Continues to Expand Investigational Supply to Support International Ebola Outbreak Response

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck, known as MSD outside the United States and Canada

Merck Makes Shipments of Investigational Ebola Zaire Vaccine V920 (rVSV∆G-ZEBOV-GP) to World Health Organization Shipments Made in the Latest Ebola Outbreak in the Democratic Republic of the Congo (DRC) Wednesday, May 30, 2018 3:15 pm EDT

Opdivo in combination with Vedanta Biosciences’ VE800

V920 is Merck's Investigational Vaccine for Ebola Zaire

Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers

Mon December 10, 2018 2:00 AM|Business Wire|About: BMY

Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers December 10, 2018 02:00 AM Eastern Standard Time NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Vedanta Biosciences

Kisqali (ribociclib)

Opdivo in combination with Vedanta Biosciences’ VE800

anti-PD-1 antibody tislelizumab

Novartis' Kisqali extends PFS in late-stage breast cancer studies

Dec. 10, 2018 7:38 AM ET|About: Novartis AG (NVS)|By: Douglas W. House, SA News Editor

KISQALI® (ribociclib) is a prescription medicine used in combination with: an aromatase inhibitor to treat pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic), as the first endocrine-based therapy; or fulvestrant to treat postmenopausal women with HR-positive, HER2-negative metastatic breast cancer as the first endocrine-based therapy or with disease progression following endocrine therapy

anti-PD-1 antibody tislelizumab

Opdivo in combination with Vedanta Biosciences’ VE800

anti-PD-1 antibody tislelizumab

BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncology Congress

Mon December 10, 2018 6:05 AM|GlobeNewswire|About: BGNE

Tislelizumab (BGB-A317) is an investigational humanized monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors.

seeking biotech alpha Sept 2019 & Dec 2018 insight

Lenti-D™ Gene Therapy

Eli Lilly and Company (LLY) and Evidation Health

Lenti-D™ Gene Therapy

bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

Wed September 18, 2019 9:25 AM|Business Wire|About: BLUE

Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of Follow-up

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE)

https://www.businesswire.com/news/home/20190918005480/en/

bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of Follow-up CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 18, 2019-- bluebird bio, Inc. (Nasdaq: BLUE)

Rubraca®▼ (rucaparib)

Eli Lilly and Company (LLY) and Evidation Health

Lenti-D™ Gene Therapy

Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019

Updated data from the Phase 2 TRITON2 trial of Rubraca in patients with advanced metastatic castration-resistant prostate cancer (mCRPC)
Exploratory ARIEL3 analysis for Rubraca maintenance treatment regimen in ovarian cancer based on response to prior platinum-based chemotherapy
Integrated safety analysis of Rubraca in ovarian cancer treatment and maintenance treatment settings

September 12, 2019 04:00 AM Eastern Daylight Time

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS)

https://seekingalpha.com/pr/17629630-clovis-oncology-highlight-expanded-data-rubraca-rucaparib-triton-ariel-clinical-programs

Rubraca® (rucaparib) tablets are a prescription medicine used for: The maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy The treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you

Eli Lilly and Company (LLY) and Evidation Health

BioArctic's alpha-synuclein antibody portfolio for Parkinson's disease

Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors

Fri December 14, 2018 6:45 AM|PR Newswire|About: LLY

Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors Lilly will leverage Evidation's Andromeda data platform to analyze large scale data aimed at uncovering novel digital measures of health INDIANAPOLIS and SAN MATEO, Calif., Dec. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Evidation Health,

BioArctic's alpha-synuclein antibody portfolio for Parkinson's disease

20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077

BioArctic's alpha-synuclein antibody portfolio for Parkinson's disease

BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance

Fri December 14, 2018 2:13 AM|PR Newswire|About: ABBV, B, BIOA

BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance

Tislelizumab (BGB-A317)

20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077

BeiGene Announces Updated Phase 1A/1B Data on Tislelizumab Presented at the European Society for Medical Oncology Immuno-Oncology Congress

Sat December 15, 2018 2:30

CAMBRIDGE, Mass. and BEIJING, China, Dec. 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) AM|GlobeNewswire|About: BGNE

Tislelizumab (BGB-A317) is an investigational humanized monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors.

20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077

Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older

Fri December 14, 2018 8:00 AM|Business Wire|About: PFE

Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older December 14, 2018 08:00 AM Eastern Standard Time NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE)

seeking biotech alpha January 2019 insight

Eli Lilly and Company (LLY) & Loxo Oncology, Inc. (LOXO)

Lilly Announces Agreement To Acquire Loxo Oncology

Mon January 7, 2019 6:30 AM|PR Newswire|About: LLY, LOXO

INDIANAPOLIS and STAMFORD, Conn., Jan. 7, 2019 /PRNewswire/ -

Lilly Announces Agreement To Acquire Loxo Oncology Jan 07, 2019, 06:30 ET INDIANAPOLIS and STAMFORD, Conn., Jan. 7, 2019 /PRNewswire/ --

Abiomed, Inc. (ABMD)

Eli Lilly and Company (LLY) & Loxo Oncology, Inc. (LOXO)

Abiomed Announces Preliminary Q3 FY 2019 Revenue of $201 Million, Up 30% Over Prior Year and Increases Full Year Guidance

Mon January 7, 2019 7:00 AM|Business Wire|About: ABMD

DANVERS, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- Abiomed, Inc. (ABMD) (NASDAQ: ABMD)

Abiomed Announces Preliminary Q3 FY 2019 Revenue of $201 Million, Up 30% Over Prior Year and Increases Full Year Guidance January 07, 2019 07:00 AM Eastern Standard Time DANVERS, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD)

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY)

Eli Lilly and Company (LLY) & Loxo Oncology, Inc. (LOXO)

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY)

Regeneron to receive $462M from Sanofi in revamped I-O collaboration

Jan. 7, 2019 7:22 AM ET|About: Regeneron Pharmaceutic... (REGN)|By: Douglas W. House, SA News Editor

January 7, 2019 at 2:30 AM EST REGENERON AND SANOFI RESTRUCTURE IMMUNO-ONCOLOGY COLLABORATION FOR DISCOVERY AND DEVELOPMENT PROGRAMS TARRYTOWN, N.Y. and PARIS, Jan. 7, 2019 /PRNewswire/ -- Companies select two clinical-stage bispecific antibodies for ongoing collaboration

Bimatoprost SR

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY)

Mon January 7, 2019 7:45 AM|PR Newswire|About: AGN

Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR (Sustained-Release) Implant for Lowering Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension - These initial data show the potential for the vast majority of patients to remain treatment free for at least 1 year - DUBLIN, Jan. 7, 2019 /PRNewswire/ -- Allergan plc, (NYSE: AGN)

Allergan (AGN)

Bimatoprost SR

Allergan (AGN)

01.07.2019 | Investors

Allergan to Establish R&D Presence in Cambridge, Massachusetts

- The facility, located in Kendall Square, is expected to open in 1Q2019 -

DUBLIN, Jan. 7, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN),

Advancing the Pipeline Key programs in development that derive from our Open Science pipeline

Celgene (CELG)

Bimatoprost SR

Allergan (AGN)

Celgene Corporation Announces 2019 Financial Guidance and Key Milestones

Mon January 7, 2019 7:30 AM|Business Wire|About: CELG

Celgene Corporation Announces 2019 Financial Guidance and Key Milestones Company achieved its latest full-year 2018 guidance; will report Q4 2018 results on January 31, 2019 Provides full-year 2019 guidance and reaffirms 2020 outlook Fedratinib NDA and REVLIMID® (AUGMENT™) sNDA submitted; ozanimod regulatory submissions on-track for Q1 2019 January 07, 2019 07:30 AM Eastern Standard Time SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG

seeking biotech alpha January 2019 insight

oral JAK3 inhibitor, PF-06651600

VYZULTA™ (latanoprostene Bunod Ophthalmic Solution, 0.024%)

Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata

Thu January 3, 2019 8:30 AM|Business Wire|About: PFE

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE)

Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata January 03, 2019 08:30 AM Eastern Standard Time NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE)

VYZULTA™ (latanoprostene Bunod Ophthalmic Solution, 0.024%)

Bausch + Lomb Announces HEALTH CANADA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution, 0.024%) for the Treatment of Glaucoma

Thu January 3, 2019 7:30 AM|Canada Newswire|About: BHC

LAVAL, QC, Jan. 3, 2019 /CNW Telbec/ - Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health (BHC) (TSX : BHC)

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension.

IQcast(TM)

VYZULTA™ (latanoprostene Bunod Ophthalmic Solution, 0.024%)

IQcast(TM)

New Prediction Feature for Hypoglycemia Now Available in Sugar.IQ(TM) Personal Diabetes Assistant App, Developed by Medtronic and IBM Watson Health

Thu January 3, 2019 9:00 AM|InPublic US|About: MDT

American Diabetes Association Issues Hypoglycemia Position Statement

Rapastinel

Vertex Pharmaceuticals (VRTX)

IQcast(TM)

Thu January 3, 2019 7:45 AM|PR Newswire|About: AGNPR Newswire

DUBLIN, Jan. 3, 2019 /PRNewswire/ -- Allergan plc (AGN)

New Data Published in the International Journal of Neuropsychopharmacology Support that Rapastinel May Produce Rapid and Sustained Antidepressant Effects Through a Potentially Novel Mechanism of Action Preclinical research demonstrated rapastinel positively modulates the NMDA receptor DUBLIN, Jan. 3, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN)

TYSABRI®, natalizumab 300 mg

Vertex Pharmaceuticals (VRTX)

First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis

Thu January 3, 2019 7:30 AM|GlobeNewswire|About: BIIB

TYSABRI® (natalizumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) to slow the worsening of symptoms common in people with MS and to decrease the number of flare-ups (relapses). TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML)

Vertex Pharmaceuticals (VRTX)

Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies

Thu January 3, 2019 8:00 AM|Business Wire|About: VRTX

Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies -Multi-year research collaboration funded by Vertex using Arbor’s proprietary research platform to enhance efforts in developing gene-editing therapies in five diseases- January 03, 2019 08:00 AM Eastern Standard Time BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Arbor Biotechnologies (Arbor

seeking biotech alpha January 2019 insight

Sprycel® (dasatinib)

Cinacalcet is a calcium-sensing receptor agonist

novel frozen formulation of Bria-IMT™

Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Wed January 2, 2019 4:25 PM|Business Wire|About: BMY

Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Sprycel is the first and only second-generation tyrosine kinase inhibitor for pediatric patients for the treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia in combination with chemotherapy Approval marks second pediatric leukemia indication for Sprycel 1 WEDNESDAY, JANUARY 2, 2019 4:25 PM EST PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY)

novel frozen formulation of Bria-IMT™

Cinacalcet is a calcium-sensing receptor agonist

novel frozen formulation of Bria-IMT™

BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference

January 02, 2019 | About: BCTXF +0% MRK +0%

Marketwired

BERKELEY, Calif., and VANCOUVER, British Columbia, Jan. 02, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (BCTXF) ("BriaCell" or the "Company")

BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference January 2, 2019 BERKELEY, Calif., and VANCOUVER, British Columbia, January 2, 2019 – BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) (“BriaCell” or the “Company”),

Cinacalcet is a calcium-sensing receptor agonist

Teva and Amgen Resolve Ongoing Dispute Over Teva’s Generic Cinacalet HCl Product

Wed January 2, 2019 8:28 PM|Business Wire|About: TEVA

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (TEVJF), (NYSE and TASE: TEVA)

Teva and Amgen Resolve Ongoing Dispute Over Teva’s Generic Cinacalet HCl Product January 02, 2019 08:28 PM Eastern Standard Time PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA)

KEYTRUDA® (pembrolizumab)

NGM313, an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex

Cinacalcet is a calcium-sensing receptor agonist

Thu January 3, 2019 6:45 AM|Business Wire|About: MRK

Merck’s KEYTRUDA® (pembrolizumab) Receives Five New Approvals in Japan, Including in Advanced Non-Small Cell Lung Cancer (NSCLC), as Adjuvant Therapy for Melanoma, and in Advanced Microsatellite Instability-High (MSI-H) Tumors KEYTRUDA is the First Anti-PD-1 Approved in Japan for the First-Line Treatment of Advanced NSCLC as Both Monotherapy and in Combination with Chemotherapy With New MSI-H Indication, KEYTRUDA is the First Cancer Therapy Approved in Japan for Use Based on a Biomarker, Regardless of Tumor Type January 03, 2019 06:45 AM Eastern Standard Time KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK)

Bristol-Myers Squibb to Acquire Celgene

NGM313, an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex

Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company

Highly Complementary Portfolios with Leading Franchises in Oncology, Immunology and Inflammation and Cardiovascular Disease
Significantly Expands Phase III Assets with Six Expected Near-Term Product Launches, Representing Greater Than $15 Billion in Revenue Potential
Registrational Trial Opportunities and Early-Stage Pipeline Position Combined Company for Sustained Leadership Underpinned by Cutting-Edge Technologies and Discovery Platforms
Strong Combined Cash Flows, Enhanced Margins and EPS Accretion of Greater Than 40% in First Full Year
Approximately $2.5 Billion of Expected Run-Rate Cost Synergies to Be Achieved by 2022

THURSDAY, JANUARY 3, 2019 6:58 AM EST

NEW YORK & SUMMIT, N.J.,--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG)

Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company January 03, 2019 06:58 AM Eastern Standard Time NEW YORK & SUMMIT, N.J.,--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion.

NGM313, an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex

Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes

Thu January 3, 2019 6:30 AM|Business Wire|About: MRK

KENILWORTH, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Merck (MRK)

Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes January 03, 2019 06:30 AM Eastern Standard Time KENILWORTH, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK)

seeking biotech alpha Sept 2019 & December 2018 insight

SPINRAZA™ (nusinersen)

PRGN-3006 UltraCAR-T is an autologous chimeric antigen receptor T-cell (CAR-T) therapy

ULTOMIRIS™ (Ravulizumab-cwvz)

Biogen Applauds Quebec Decision to Cover SPINRAZA™ (nusinersen) for a broad population of SMA Patients

Thu December 20, 2018 12:19 PM|GlobeNewswire|About: BIIB

SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

ULTOMIRIS™ (Ravulizumab-cwvz)

PRGN-3006 UltraCAR-T is an autologous chimeric antigen receptor T-cell (CAR-T) therapy

ULTOMIRIS™ (Ravulizumab-cwvz)

Alexion Receives Early FDA Approval for ULTOMIRIS™ (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Fri December 21, 2018 11:23 AM|Business Wire|About: ALXN

lexion Receives Early FDA Approval for ULTOMIRIS™ (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) - ULTOMIRIS has the potential to become the new standard of care for both complement inhibitor-naïve patients and patients receiving SOLIRIS® (eculizumab) - December 21, 2018 11:23 AM Eastern Standard Time BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

PRGN-3006 UltraCAR-T is an autologous chimeric antigen receptor T-cell (CAR-T) therapy

Fri December 21, 2018 12:35 PM|PR Newswire|About: XON

Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T™ Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndrome (MDS) GERMANTOWN, Md., Dec. 21, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON)

pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor,

PRGN-3006 UltraCAR-T is an autologous chimeric antigen receptor T-cell (CAR-T) therapy

Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma

Fri September 27, 2019 8:00 AM|Business Wire|About: INCY

Data presented at ESMO support the planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pemigatinib before the end of 2019
Investor conference call and webcast scheduled for today, September 27, at 5:00 p.m. CEST (11:00 a.m. EDT)

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (INCY)

Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 27, 2019-- Incyte (Nasdaq:INCY)

VAXELIS(TM

pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor,

ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder

Sanofi: FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine

FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine

PARIS and KENILWORTH, N.J. - December 26, 2018

Vaxelis is a vaccine containing active substances derived from diphtheria, tetanus, pertussis and Haemophilus influenzae type-b bacteria, the hepatitis B virus, and inactivated polioviruses. It is used in babies and toddlers aged from six weeks to protect against the following infectious diseases: diphtheria (a highly contagious disease that affects the throat and skin, and can cause damage to the heart and other organs); tetanus (lockjaw, usually caused by infection of a wound); pertussis (whooping cough); hepatitis B (a viral liver infection); poliomyelitis (polio, a disease that affects the nerves and can lead to muscle weakness or paralysis); invasive diseases (such as pneumonia and meningitis) caused by H. influenzae type-b bacteria (Hib).

ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder

pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor,

ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder

Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder

Fri December 21, 2018 3:19 PM|Business Wire|About: TEVA

Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder Bluetooth® Wireless Technology, Flow Sensors and Companion Mobile Application Track Inhaler Use in People with Asthma & COPD December 21, 2018 03:19 PM Eastern Standard Time JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA

seeking biotech alpha December 2018 insight

Upadacitinib (ABT-494)

Bevespi Aerosphere (glycopyrronium/formoterol fumarate)

Upadacitinib (ABT-494)

AbbVie Submits New Drug Application to U.S. FDA and Marketing Authorization Application to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis

Thu December 20, 2018 8:50 AM|PR Newswire|About: ABBV

AbbVie Submits New Drug Application to U.S. FDA and Marketing Authorization Application to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis NORTH CHICAGO, Ill., Dec. 20, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV)

XTANDI® (enzalutamide)

Bevespi Aerosphere (glycopyrronium/formoterol fumarate)

Upadacitinib (ABT-494)

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

Thu December 20, 2018 9:00 AM|Business Wire|About: ALPMY, PFE

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer TOKYO and NEW YORK, Dec. 20, 2018 /PRNewswire/

Bevespi Aerosphere (glycopyrronium/formoterol fumarate)

Gilead Sciences, Inc. (GILD) and Agenus Inc. (NASDAQ: AGEN)

Bevespi Aerosphere approved in the EU for chronic obstructive pulmonary disease

20 December 2018 13:45 GMT

BEVESPI AEROSPHERE is a prescription medicine used to treat chronic obstructive pulmonary disease (COPD). COPD includes chronic bronchitis, emphysema, or both. BEVESPI AEROSPHERE is used long term as 2 inhalations, 2 times each day in the morning and in the evening, to improve symptoms of COPD for better breathing. Do not use BEVESPI AEROSPHERE to treat sudden symptoms of COPD; it won't replace a rescue inhaler. BEVESPI AEROSPHERE is not for the treatment of asthma.

Gilead Sciences, Inc. (GILD) and Agenus Inc. (NASDAQ: AGEN)

Gilead Sciences, Inc. (GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK)

Gilead Sciences, Inc. (GILD) and Agenus Inc. (NASDAQ: AGEN)

December 20, 2018

Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies

FOSTER CITY, Calif. & LEXINGTON, Mass.--(BUSINESS WIRE)--Dec. 20, 2018-- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc.(NASDAQ: AGEN)

Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies

Gilead Sciences, Inc. (GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK)

Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases

Wed December 19, 2018 8:01 AM|Business Wire|About: GILD, SRRK

Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases

KEYTRUDA® (pembrolizumab)

Gilead Sciences, Inc. (GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK)

Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial

Thu December 20, 2018 4:15 PM|Business Wire|About: MRK

Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial December 20, 2018 04:15 PM Eastern Standard Time KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada

seeking biotech alpha December 2018 insight

KEYTRUDA® (pembrolizumab)

Merck KGaA, Darmstadt, Germany, will assign its exclusive CAR-T development rights to Intrexon

KEYTRUDA® (pembrolizumab)

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer

Wed December 19, 2018 4:13 PM|Business Wire|About: MRK

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer

LYNPARZA® (olaparib)

Merck KGaA, Darmstadt, Germany, will assign its exclusive CAR-T development rights to Intrexon

KEYTRUDA® (pembrolizumab)

LYNPARZA® (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer

Wed December 19, 2018 4:01 PM|Business Wire|About: AZN

LYNPARZA® (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer AstraZeneca and Merck’s LYNPARZA reduced the risk of disease progression or death by 70% compared to placebo following response to platinum-based chemotherapy First PARP inhibitor approved in 1st-line maintenance for BRCAm advanced ovarian cancer December 19, 2018 04:01 PM Eastern Standard Time WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada)

Merck KGaA, Darmstadt, Germany, will assign its exclusive CAR-T development rights to Intrexon

Intrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen's Vision for Full Developmental Autonomy of its CAR-T Program

Thu December 20, 2018 7:30 AM|PR Newswire|About: XON

Intrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen's Vision for Full Developmental Autonomy of its CAR-T Program - Merck KGaA, Darmstadt, Germany, to assign its Chimeric A GERMANTOWN, Md., Dec. 20, 2018 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON)

KEYTRUDA® (pembrolizumab)

Merck KGaA, Darmstadt, Germany, will assign its exclusive CAR-T development rights to Intrexon

KEYTRUDA is a prescription medicine used to treat:

a kind of skin cancer called melanoma. It may be used when your melanoma has spread or cannot be removed by surgery (advanced melanoma).
a kind of lung cancer called non–small cell lung cancer (NSCLC).
- It may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type called “nonsquamous” and your tumor does not have an abnormal “EGFR” or “ALK” gene.
- It may be used with the chemotherapy medicines carboplatin and either paclitaxel or nab-paclitaxel as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type called “squamous”.
- It may be used alone as your first treatment when your lung cancer has spread (advanced NSCLC) and tests positive for “PD‑L1” and your tumor does not have an abnormal “EGFR” or “ALK” gene.
- It may also be used alone for advanced NSCLC if you have tried chemotherapy that contains platinum and it did not work or is no longer working and your lung cancer tests positive for “PD‑L1” and, if your tumor has an abnormal “EGFR” or “ALK” gene, you have also received an “EGFR” or “ALK” inhibitor medicine that did not work or is no longer working.
a kind of cancer called head and neck squamous cell cancer (HNSCC). It may be used when your HNSCC has returned or spread and you have received chemotherapy that contains platinum and it did not work or is no longer working.
a kind of cancer called classical Hodgkin lymphoma (cHL). It may be used for cHL in adults and children when you have tried a treatment and it did not work or when your cHL has returned after you received 3 or more types of treatment.
a kind of cancer called primary mediastinal B-cell lymphoma (PMBCL). It may be used for PMBCL in adults and children when you have tried a treatment and it did not work oryour PMBCL has returned after you received 2 or more types of treatment.
a kind of bladder and urinary tract cancer called urothelial carcinoma. It may be used when your bladder or urinary tract cancer has spread or cannot be removed by surgery (advanced urothelial cancer) and you are not able to receive chemotherapy that contains a medicine called cisplatin, and your tumor tests positive for PD‑L1, or you are not able to receive a medicine called cisplatin or carboplatin, or you have received chemotherapy that contains platinum, and it did not work or is no longer working.
a kind of cancer that is shown by a laboratory test to be a microsatellite instability-high (MSI‑H) or a mismatch repair deficient (dMMR) solid tumor. It may be used in adults and children to treat:
- cancer that has spread or cannot be removed by surgery (advanced cancer), and
- has progressed following treatment, and you have no satisfactory treatment options, or
- you have colon or rectal cancer, and you have received chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan but it did not work or is no longer working.
It is not known if KEYTRUDA is safe and effective in children with MSI-H cancers of the brain or spinal cord (central nervous system cancers).
a kind of stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that tests positive for “PD‑L1.” It may be used when your stomach cancer:
- has returned or spread (advanced gastric cancer), and
- you have received 2 or more types of chemotherapy including fluoropyrimidine and chemotherapy that contains platinum, and it did not work or is no longer working, and
- if your tumor has an abnormal “HER2/neu” gene, you also received a HER2/neu‑targeted medicine and it did not work or is no longer working.
a kind of cancer called cervical cancer that tests positive for “PD-L1.” It may be used when your cervical cancer has returned, or has spread or cannot be removed by surgery (advanced cervical cancer), and you have received chemotherapy, and it did not work or is no longer working.
a kind of liver cancer called hepatocellular carcinoma. It may be used after you have received the medicine sorafenib.

PD‑L1 = programmed death ligand 1;
EGFR = epidermal growth factor receptor;
ALK = anaplastic lymphoma kinase;
HER2/neu = human epidermal growth factor receptor 2.

LYNPARZA® (olaparib)

KEYTRUDA® (pembrolizumab)

LYNPARZA® (olaparib)

LYNPARZA is a prescription medicine used to treat adults who have:

advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that LYNPARZA is right for you
ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, as maintenance treatment, when the cancer has come back. LYNPARZA is used after the cancer has responded to treatment with platinum-based chemotherapy
advanced ovarian cancer with a certain type of abnormal inherited BRCA gene, and have received treatment with 3 or more prior types of chemotherapy medicines. Your healthcare provider will perform a test to make sure that LYNPARZA is right for you

LYNPARZA® (olaparib) approved by US FDA for first-line maintenance therapy in BRCA-mutated advanced ovarian cancer 19 December 2018 AstraZeneca and Merck’s LYNPARZA reduced the risk of disease progression or death by 70% compared to placebo following response to platinum-based chemotherapy First PARP inhibitor approved in 1st-line maintenance for BRCAm advanced ovarian cancer

Nplate® (romiplostim)

KEYTRUDA® (pembrolizumab)

LYNPARZA® (olaparib)

Amgen Submits Supplemental Biologics License Application For Nplate® (romiplostim)

Wed December 19, 2018 4:00 PM|PR Newswire|About: AMGN

Nplate® is a prescription medicine used to treat low blood platelet counts (thrombocytopenia) in: adults with chronic immune thrombocytopenia (ITP) when certain medicines or surgery to remove your spleen have not worked well enough.

seeking biotech alpha December 2018 insight

Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO)

Lilly Announces Financial Guidance, Reviews Commercial Performance, and Highlights Promising Pipeline Opportunities at Investment Community Meeting

12/19/2018

INDIANAPOLIS, Dec. 19, 2018 /PRNewswire/ -

2019 revenue is expected to be between $25.3 billion and $25.8 billion

Our growing portfolio of medicines includes treatments in the areas of oncology, cardiovascular, diabetes, critical care, neuroscience, men’s health and musculoskeletal fields.

Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO)

Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies

12/18/2018

INDIANAPOLIS and BERKLEY, Calif., Dec. 18, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO)

Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies December 18, 2018 4:15 p.m. ET INDIANAPOLIS and BERKLEY, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO)

Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO)

Eli Lilly and Company (LLY)

Lilly Announces 15 Percent Dividend Increase

Wed December 19, 2018 6:25 AM|PR Newswire|About: LLY

Lilly Announces 15 Percent Dividend Increase 12/19/2018 INDIANAPOLIS, Dec. 19, 2018 /PRNewswire/

STING Pathway Activator technology

Eli Lilly and Company (LLY)

STING is known to be a central mediator of innate immunity. When stimulated, STING induces the expression of type I interferon, cytokines and T cell recruitment factors that result in the activation of macrophages and dendritic cells, innate effector cells such as natural killer (NK) cells, and priming of tumor-specific T cells.

STING Pathway Activator technology

Aduro’s STING Pathway Activator platform is based on the activation of the cytoplasmic STING (Stimulator of Interferon Genes) receptor to lead to a tumor-specific immune response.

Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies

STING Pathway Activator technology

Natural STING Pathway Activators are small molecules expressed by bacteria and immune cells. Aduro has established pioneering expertise in STING Pathway Activator technology and, working in collaboration with academic leaders in the field, has developed synthetic STING Pathway Activators with significantly higher activity than the natural STING ligands produced by bacteria and mammalian cells. These synthetic STING Pathway Activators are being developed for direct injection into tumors to stimulate an immune response against antigens present in the tumor. The process is expected to use the tumor itself as a “vaccine,” enabling the induction of a tumor-specific immune response that is unique to the treated individual; an off-the-shelf small molecule approach to personalized immunotherapy.

seeking biotech alpha December 2018 insight

www.factsabouttalc.com.

Incyte (NASDAQ:INCY) and Innovent Biologics, Inc. (Innovent) (HKEX: 01801)

ABP 710, a biosimilar candidate to REMICADE® (infliximab).

NEW BRUNSWICK, N.J., Dec. 14, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today issued the following statement regarding speculation about the safety of our products.

The Reuters article is one-sided, false, and inflammatory. Johnson & Johnson's baby powder is safe and asbestos-free. Studies of more than 100,000 men and women show that talc does not cause cancer or asbestos-related disease. Thousands of independent tests by regulators and the world's leading labs prove our baby powder has never contained asbestos. Johnson & Johnson will continue to defend the safety of our product. For the truth and facts about talc, please go to www.factsabouttalc.com.

The Reuters article is wrong in three key areas: The article ignores that thousands of tests by J&J, regulators, leading independent labs, and academic institutions have repeatedly shown that our talc does not contain asbestos. The article ignores that J&J has cooperated fully and openly with the U.S. FDA and other global regulators, providing them with all the information they requested over decades. We have also made our cosmetic talc mines and processed talc available to regulators for testing. Regulators have tested both, and they have always found our talc to be asbestos-free. The article ignores that J&J has always used the most advanced testing methods available to confirm that our cosmetic talc does not contain asbestos. Every method available to test J&J's talc for asbestos has been used by J&J, regulators, or independent experts, and all of these methods have all found that our cosmetic talc is asbestos-free.

ABP 710, a biosimilar candidate to REMICADE® (infliximab).

Incyte (NASDAQ:INCY) and Innovent Biologics, Inc. (Innovent) (HKEX: 01801)

ABP 710, a biosimilar candidate to REMICADE® (infliximab).

Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration

Mon December 17, 2018 9:00 AM|PR Newswire|About: AMGN

Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration Filing for ABP 710, a Biosimilar Candidate to Infliximab, Supported by Phase 3 Study in Patients With Moderate-to-Severe Rheumatoid Arthritis THOUSAND OAKS, Calif., Dec. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN)

Incyte (NASDAQ:INCY) and Innovent Biologics, Inc. (Innovent) (HKEX: 01801)

Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China

Sun December 16, 2018 5:40 PM|Business Wire|About: INCY

Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China WILMINGTON, Del. & SUZHOU, China--(BUSINESS WIRE)--Incyte (NASDAQ:INCY) and Innovent Biologics, Inc. (Innovent) (HKEX: 01801)

tislelizumab

Kineta Immuno-Oncology, LLC (KIO), a subsidiary of Kineta, Inc., & Pfizer Inc. (NYSE: PFE)

Incyte (NASDAQ:INCY) and Innovent Biologics, Inc. (Innovent) (HKEX: 01801)

BeiGene's tislelizumab shows positive action in early-stage cancer study

Dec. 17, 2018 12:09 PM ET|About: BeiGene (BGNE)|By: Douglas W. House, SA News Editor

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors

Kineta Immuno-Oncology, LLC (KIO), a subsidiary of Kineta, Inc., & Pfizer Inc. (NYSE: PFE)

Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies

Mon December 17, 2018 8:00 AM|PR Newswire|About: PFE

Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies Kineta Immuno-Oncology to receive $15 million upfront and will be eligible to receive up to $505 million in potential research, development and sales milestone payments SEATTLE, Dec. 17, 2018 /PRNewswire/ -- Kineta Immuno-Oncology, LLC (KIO), a subsidiary of Kineta, Inc., today announced that it has entered into a strategic research collaboration with Pfizer Inc. (NYSE: PFE)

Kineta Immuno-Oncology, LLC (KIO), a subsidiary of Kineta, Inc., & Pfizer Inc. (NYSE: PFE)

Chugai's Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

Wed December 19, 2018 3:00 AM|Business Wire|About: CHGCY, RHHBY

Chugai's Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders －Designation is Seventh for Chugai Originated Drug－ December 19, 2018 03:00 AM Eastern Standard Time TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519

seeking biotech alpha December 2018 insight

Verzenio® (abemaciclib)

InterStim(TM) smart programmer

Verzenio® (abemaciclib)

Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis

Tue December 18, 2018 6:45 AM|PR Newswire|About: LLY

Verzenio is a prescription medicine used to treat a type of breast cancer. It is a medicine you can take if: You have a type of breast cancer called HR+/HER2− (hormone receptor positive/human epidermal growth factor receptor 2 negative) and the cancer has spread to other parts of the body (metastasized) Verzenio is given in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, in combination with fulvestrant in women whose disease has progressed after hormonal therapy, or alone in women whose disease has progressed after hormone therapy and prior chemotherapy

NaV1.8 inhibitor VX-150

InterStim(TM) smart programmer

Verzenio® (abemaciclib)

Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150

Tue December 18, 2018 8:30 AM|Business Wire|About: VRTX

Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150 -Treatment with the NaV1.8 inhibitor VX-150 showed significant relief of pain in patients with small fiber neuropathy and was generally well tolerated- -Third positive Phase 2 proof-of-concept study for VX-150 further validates the potential role of NaV1.8 inhibition for the treatment of multiple pain conditions- December 18, 2018 08:30 AM Eastern Standard Time BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX

InterStim(TM) smart programmer

FDA Approves Smart Programmer for the InterStim System

(GLOBE NEWSWIRE via COMTEX) --Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence

DUBLIN - December 17, 2018 - Medtronic plc (NYSE:MDT)

INTERSTIM THERAPY FOR URINARY CONTROL InterStim Therapy for Urinary Control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.

Johnson & Johnson (JNJ)

Bristol-Myers Squibb Company (BMY), and Boston Medical Center

InterStim(TM) smart programmer

Johnson & Johnson Announces $5 Billion Share Repurchase Program

Mon December 17, 2018 4:22 PM|PR Newswire|About: JNJ

NEW BRUNSWICK, N.J., Dec. 17, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ)

Johnson & Johnson Announces $5 Billion Share Repurchase Program NEW BRUNSWICK, N.J., Dec. 17, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ)

Bristol-Myers Squibb Company (BMY), and Boston Medical Center

Bristol-Myers Squibb and Boston Medical Center Announce Research Collaboration to Investigate Markers of Immuno-Oncology Response and Resistance

Mon December 17, 2018 4:30 PM|Business Wire|About: BMY

NEW YORK & BOSTON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (BMY) (NYSE:BMY), and Boston Medical Center,

Bristol-Myers Squibb and Boston Medical Center Announce Research Collaboration to Investigate Markers of Immuno-Oncology Response and Resistance December 17, 2018 04:30 PM Eastern Standard Time NEW YORK & BOSTON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY), and Boston Medical Cen

China is the first country to approve roxadustat

Bristol-Myers Squibb Company (BMY), and Boston Medical Center

FibroGen's roxadustat OK'd in China for CKD patients on dialysis

Dec. 18, 2018 7:01 AM ET|By: Douglas W. House, SA News Editor

Roxadustat approved in China for the treatment of anaemia in chronic kidney disease patients on dialysis AstraZeneca today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China)

seeking biotech alpha December 2018 insight

First Approval for KEYTRUDA in an Adjuvant Setting in the European Union

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma

Mon December 17, 2018 6:30

AM|Business Wire|About: MRK

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma December 17, 2018 06:30 AM Eastern Standard Time KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK),

Pyramid Biosciences, Inc. & AZN

First Approval for KEYTRUDA in an Adjuvant Setting in the European Union

Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases

Mon December 17, 2018 7:00 AM|PR Newswire|About: AZN

Pyramid Biosciences, Inc. (www.pyramidbio.com)

Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases WALTHAM, Mass., Dec. 17, 2018 /PRNewswire/ -- Pyramid Biosciences, Inc. (www.pyramidbio.com),

Bristol-Myers Squibb and H3 Biomedicine

First Approval for KEYTRUDA in an Adjuvant Setting in the European Union

Bristol-Myers Squibb and H3 Biomedicine

Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3’s RNA Splicing Platform

Mon December 17, 2018 6:59 AM|Business Wire|About: BMY

Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3’s RNA Splicing Platform December 17, 2018 06:59 AM Eastern Standard Time NEW YORK, TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and its U.S.-based precision medicine research & development subsidiary H3 Biomedicine, Inc. (Massachusetts, “H3”)

Taltz® (ixekizumab)

Sprycel (dasatinib)

Bristol-Myers Squibb and H3 Biomedicine

Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis

Mon December 17, 2018 6:45 AM|PR Newswire|About: LLY

Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis INDIANAPOLIS, Dec. 17, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)

Diroximel Fumarate

Sprycel (dasatinib)

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

Mon December 17, 2018 7:30 AM|PR Newswire|About: ALKS, BIIB

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis DUBLIN and CAMBRIDGE, Mass., Dec. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB)

Sprycel (dasatinib)

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Mon December 17, 2018 6:59 AM|Business Wire|About: BMY

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia December 17, 2018 06:59 AM Eastern Standard Time PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY)

seeking biotech alpha December 2018 insight

Baricitinib

Merck (MRK) & Instituto Butantan

FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)

Thu December 13, 2018 6:45 AM|PR Newswire|About: INCY, LLY

FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE) INDIANAPOLIS, Dec. 13, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY)

Merck (MRK) & Instituto Butantan

Merck and Instituto Butantan Announce Collaboration Agreement to Develop Vaccines to Protect Against Dengue Infections

Wed December 12, 2018 10:30 AM|Business Wire|About: MRK

Merck and Instituto Butantan Announce Collaboration Agreement to Develop Vaccines to Protect Against Dengue Infections December 12, 2018 10:30 AM Eastern Standard Time KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Instituto Butantan, Sao Paulo, Brazil

Amgen & Magellan Rx

Merck (MRK) & Instituto Butantan

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute

Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions

Tue December 11, 2018 4:00 PM|PR Newswire|About: AMGN

Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions THOUSAND OAKS, Calif., Dec. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN)

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

Thu December 13, 2018 6:30 AM|PR Newswire|About: LLY

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 13, 2018 /PRNewswire/ -

ORKAMBI® (lumacaftor/ivacaftor)

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute

ORKAMBI® (lumacaftor/ivacaftor)

Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease

Thu December 13, 2018 8:00 AM|Business Wire|About: VRTX

Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease December 13, 2018 08:00 AM Eastern Standard Time BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX)

TREMFYA® (guselkumab)

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute

ORKAMBI® (lumacaftor/ivacaftor)

New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48

Wed December 12, 2018 7:00 AM|PR Newswire|About: JNJ

TREMFYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light or UV light).

seeking biotech alpha December 2018 insight

BIIB067 (IONIS-SOD1RX),

Bria-IMT™, with pembrolizumab [KEYTRUDA®

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data

Thu December 6, 2018 7:30 AM|GlobeNewswire|About: AKCA, BIIB, IONS

Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases.

Bria-IMT™, with pembrolizumab [KEYTRUDA®

BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference

Thu December 6, 2018 8:30 AM|GlobeNewswire|About: BCTXF, MRK

BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study September 26, 2018

Illumina, Inc. (ILMN)

Bria-IMT™, with pembrolizumab [KEYTRUDA®

PI3K inhibitor BYL719 (alpelisib)

Illumina Announces a New Genotyping Array and Scientific Contribution to Three Genome Centers to Support the All of Us Research Program

Thu December 6, 2018 4:05 PM|Business Wire|About: ILMN

Illumina Announces a New Genotyping Array and Scientific Contribution to Three Genome Centers to Support the All of Us Research Program

PI3K inhibitor BYL719 (alpelisib)

Bausch Health Companies Inc. (BHC)

PI3K inhibitor BYL719 (alpelisib)

Novartis' alpelisib improved PFS in certain breast cancer patients in late-stage study

Dec. 6, 2018 12:07 PM ET|By: Douglas W. House, SA News Editor

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1)

Bausch Health Companies Inc. (BHC)

Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses

Wed December 5, 2018 8:00 AM|PR Newswire|About: BHC

Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses

Bristol-Myers Squibb Company (BMY)

Bausch Health Companies Inc. (BHC)

Bristol-Myers Squibb Announces Dividend Increase

Thu December 6, 2018 4:15 PM|Business Wire|About: BMY

Bristol-Myers Squibb Announces Dividend Increase NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY

seeking biotech alpha December 2018 insight

Stryker Corporation (SYK)

DARZALEX (daratumumab) when added to Celgene's (CELG +0.7%) REVLIMID (lenalidomide)

IMBRUVICA® (ibrutinib) plus rituximab

Stryker increases dividend 11%, declaring a $0.52 per share quarterly dividend

Tue December 4, 2018 3:30 PM|GlobeNewswire|About: SYK

Stryker increases dividend 11%, declaring a $0.52 per share quarterly dividend << Back Kalamazoo, Michigan, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Kalamazoo, Michigan – December 4, 2018 – Stryker Corporation (NYSE:SYK)

IMBRUVICA® (ibrutinib) plus rituximab

DARZALEX (daratumumab) when added to Celgene's (CELG +0.7%) REVLIMID (lenalidomide)

IMBRUVICA® (ibrutinib) plus rituximab

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018

Tue December 4, 2018 11:52 AM|PR Newswire|About: ABBV

DARZALEX (daratumumab) when added to Celgene's (CELG +0.7%) REVLIMID (lenalidomide)

Johnson & Johnson's Darzalex shows positive effect in certain multiple myeloma patients;

Dec. 4, 2018 11:56 AM ET|By: Douglas W. House, SA News Editor

DARZALEX® is a prescription medicine used to treat multiple myeloma: In combination with the medicines lenalidomide and dexamethasone or bortezomib and dexamethasone, in people who have received at least one prior medicine to treat multiple myeloma In combination with the medicines pomalidomide and dexamethasone in people who have received at least two prior medicines to treat multiple myeloma, including lenalidomide and a proteasome inhibitor Alone in people who have received at least three prior medicines to treat multiple myeloma, including a proteasome inhibitor and an immunomodulatory agent, or did not respond to a proteasome inhibitor and an immunomodulatory agent

Kadcyla® (ado-trastuzumab emtansine)

cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®)

DARZALEX (daratumumab) when added to Celgene's (CELG +0.7%) REVLIMID (lenalidomide)

Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Wed December 5, 2018 8:15 AM|Business Wire|About: RHHBY

Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Tecentriq® (atezolizumab)

cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®)

FDA Grants Priority Review to Genentech’s Tecentriq in Combination with Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer

Wed December 5, 2018 1:00 AM|Business Wire|About: RHHBY

FDA Grants Priority Review to Genentech’s Tecentriq in Combination with Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer

cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®)

Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma

Wed December 5, 2018 1:30 AM|Business Wire|About: EXEL, IPSEY

Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma – Clinical trial will also explore single-agent activity of cabozantinib in the first-line setting

seeking biotech alpha December 2018 insight

IMBRUVICA® (ibrutinib) plus obinutuzumab (Gazyva®)

December 3, 2018

IMBRUVICA® (ibrutinib) Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NORTH CHICAGO, Ill., Dec. 3, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV

Ruxolitinib (Jakafi®)

IMBRUVICA® (ibrutinib) plus obinutuzumab (Gazyva®)

Results of REACH1 Study of Ruxolitinib (Jakafi®) for the Treatment of Acute Graft-Versus-Host Disease Demonstrate Rapid and Durable Patient Benefit

Mon December 3, 2018 10:00 AM|Business Wire|About: INCY

Jakafi is a prescription medicine used to treat people with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it. Jakafi is also used to treat certain types of myelofibrosis.

tislelizumab

IMBRUVICA® (ibrutinib) plus obinutuzumab (Gazyva®)

Hemlibra® (emicizumab-kxwh)

BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting

Mon December 3, 2018 2:15 PM|GlobeNewswire|About: BGNE

BeiGene Pipeline

Hemlibra® (emicizumab-kxwh)

Genentech’s Hemlibra (emicizumab-kxwh) Provided Sustained Bleed Control in the Largest Pivotal Study to Date of Children With Hemophilia A With Factor VIII Inhibitors

Mon December 3, 2018 1:30 PM|Business Wire|About: CHGCY, RHHBY

Genentech’s Hemlibra (emicizumab-kxwh) Provided Sustained Bleed Control in the Largest Pivotal Study to Date of Children With Hemophilia A With Factor VIII Inhibitors

NCCN Oncology Research

Hemlibra® (emicizumab-kxwh)

Venclexta® (venetoclax)

NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment

Mon December 3, 2018 10:15 AM|PR Newswire|About: LLY

NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment Project to focus on preclinical and clinical research with cyclin dependent kinase (CDK)4 & 6 inhibitors

Venclexta® (venetoclax)

Hemlibra® (emicizumab-kxwh)

Venclexta® (venetoclax)

New Venclexta® Data Demonstrate Deep Responses in Two of the Most Common Types of Leukemia

Mon December 3, 2018 1:30 PM|Business Wire|About: RHHBY

VENCLEXTA® (venetoclax tablets) is indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

seeking biotech alpha December 2018 insight

REGN1979

venetoclax (VENCLEXTA® or VENCLYXTO®) in combination with rituximab (VenR)

Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Sat December 1, 2018 12:00 PM|PR Newswire|About: REGN

TARRYTOWN, N.Y., Dec. 1, 2018 /PRNewswire/

December 1, 2018 at 12:00 PM EST Back REGENERON PRESENTS POSITIVE DATA AT ASH FOR REGN1979 CD20XCD3 BISPECIFIC ANTIBODY IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA TARRYTOWN, N.Y., Dec. 1, 2018 /PRNewswire/ --

venetoclax (VENCLEXTA® or VENCLYXTO®) in combination with rituximab (VenR)

AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course

Sat December 1, 2018 5:47 PM|PR Newswire|About: ABBV

VENCLEXTA is a prescription medicine used: to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least 1 prior treatment. in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly-diagnosed acute myeloid leukemia (AML) who: are 75 years of age or older, or have other medical conditions that prevent the use of standard chemotherapy.

IMBRUVICA® (ibrutinib)

venetoclax (VENCLEXTA® or VENCLYXTO®) in combination with rituximab (VenR)

IMBRUVICA® (ibrutinib)

IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a Bruton's Tyrosine Kinase Inhibitor to Date

Sun December 2, 2018 12:00 PM|PR Newswire|About: ABBV

IMBRUVICA® (ibrutinib) is a prescription medicine used to treat adults with: Mantle cell lymphoma (MCL) who have received at least one prior treatment Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion Waldenström's macroglobulinemia (WM) Marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment Chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy

REFLECTIONS B328-06,

REVLIMID® (lenalidomide) in combination with rituximab (R2)

IMBRUVICA® (ibrutinib)

Pfizer's Rituxan biosimilar successful in late-stage study; shares up 1% premarket

Dec. 3, 2018 7:08 AM ET|About: Pfizer Inc. (PFE)|By: Douglas W. House, SA News Editor

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

REVLIMID® (lenalidomide) in combination with rituximab (R2)

Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R²) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018

Sun December 2, 2018 7:35 PM|Business Wire|About: CELG

Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018

ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab)

REVLIMID® (lenalidomide) in combination with rituximab (R2)

Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting

Sat December 1, 2018 12:00 PM|Business Wire|About: SGEN

Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting

seeking biotech alpha is biotecMAX 生物技术最大 10/1/2022 the heart of biotech

seeking biotech alpha Sept 2019 & December 2018 insight

Nplate® (Romiplostim)

HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®

ADCETRIS® (brentuximab vedotin)

ADCETRIS® (brentuximab vedotin)

HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®

ADCETRIS® (brentuximab vedotin)

HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®

HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®

ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin®* (bevacizumab),

ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin®* (bevacizumab),

ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin®* (bevacizumab),

ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin®* (bevacizumab),

INGREZZA® (valbenazine)

ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin®* (bevacizumab),

Enfortumab Vedotin Plus Pembrolizumab

Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®

- Data Examine Effect of Opicapone on COMT Enzyme and Levodopa Concentration in Patients with Parkinson's Disease

- Phase 1b Data Analyze Parkinson's Disease Progression in Patients Treated with Gene Therapy, VY-AADC

Enfortumab Vedotin Plus Pembrolizumab

ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin®* (bevacizumab),

Enfortumab Vedotin Plus Pembrolizumab

Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the European Society for Medical Oncology (ESMO) 2019 Congress

seeking biotech alpha Sept 2019 & December 2018 insight

Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy)

Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy)

Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy)

Amgen (AMGN)

Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy)

Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy)

V920 is Merck's Investigational Vaccine for Ebola Zaire

Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy)

V920 is Merck's Investigational Vaccine for Ebola Zaire

FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus

Opdivo in combination with Vedanta Biosciences’ VE800

Opdivo in combination with Vedanta Biosciences’ VE800

V920 is Merck's Investigational Vaccine for Ebola Zaire

Kisqali (ribociclib)

Opdivo in combination with Vedanta Biosciences’ VE800

anti-PD-1 antibody tislelizumab

anti-PD-1 antibody tislelizumab

Opdivo in combination with Vedanta Biosciences’ VE800

anti-PD-1 antibody tislelizumab

seeking biotech alpha Sept 2019 & Dec 2018 insight

Lenti-D™ Gene Therapy

Eli Lilly and Company (LLY) and Evidation Health

Lenti-D™ Gene Therapy

bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

Rubraca®▼ (rucaparib)

Eli Lilly and Company (LLY) and Evidation Health

Lenti-D™ Gene Therapy

Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019

Eli Lilly and Company (LLY) and Evidation Health

Eli Lilly and Company (LLY) and Evidation Health

BioArctic's alpha-synuclein antibody portfolio for Parkinson's disease

BioArctic's alpha-synuclein antibody portfolio for Parkinson's disease

20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077

BioArctic's alpha-synuclein antibody portfolio for Parkinson's disease

Tislelizumab (BGB-A317)

20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077

20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077

20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077

20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077

20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077

seeking biotech alpha January 2019 insight

Eli Lilly and Company (LLY) & Loxo Oncology, Inc. (LOXO)

Eli Lilly and Company (LLY) & Loxo Oncology, Inc. (LOXO)

Eli Lilly and Company (LLY) & Loxo Oncology, Inc. (LOXO)

Abiomed, Inc. (ABMD)

Eli Lilly and Company (LLY) & Loxo Oncology, Inc. (LOXO)

Eli Lilly and Company (LLY) & Loxo Oncology, Inc. (LOXO)

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY)

Eli Lilly and Company (LLY) & Loxo Oncology, Inc. (LOXO)

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY)

Bimatoprost SR

Bimatoprost SR

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY)

Allergan (AGN)

Bimatoprost SR